Can-Fite Reports Positive Phase IIa Results for Namodenoson in Pancreatic Cancer
Bitget2026/11/06 12:23- Can-Fite BioPharma will pursue licensing and strategic partnerships at BIO-Europe 2026 in Cologne, Germany, November 9-11.
- Namodenoson’s positive Phase IIa pancreatic cancer results, already presented at ESMO 2026, showed favorable safety and encouraging exploratory survival findings.
- A pivotal Phase III liver cancer trial recorded longer-than-anticipated blinded overall survival across participants; an interim analysis is planned.
- Piclidenoson’s pivotal Phase III psoriasis program reached its prespecified interim analysis stage, with results expected in the first quarter of 2027.
- Existing regional licensing agreements have generated approximately $20 million in upfront and milestone payments, with potential additional milestones and royalties.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Crypto prices
More
